Trading Report: Today: Wedbush Securities Inc. Raises Stake in Omeros Corporation (OMER)

Today: Wedbush Securities Inc. Raises Stake in Omeros Corporation (OMER)

Wedbush Securities Inc. boosted its position in Omeros Corporation (NASDAQ:OMER) by 8.6% during the third quarter, Holdings Channel reports. The firm owned 92,635 shares of the biopharmaceutical company’s stock after buying an additional 7,372 shares during the period. Wedbush Securities Inc. owned approximately 0.24% of Omeros Corporation worth $1,034,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Investment Management LLC boosted its position in Omeros Corporation by 12.6% in the second quarter. BlackRock Investment Management LLC now owns 154,233 shares of the biopharmaceutical company’s stock worth $1,623,000 after buying an additional 17,226 shares during the period. BlackRock Advisors LLC boosted its position in Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 173 shares during the period. Vanguard Group Inc. boosted its position in Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock worth $15,045,000 after buying an additional 32,401 shares during the period. Brown Advisory Inc. boosted its position in Omeros Corporation by 4.0% in the second quarter. Brown Advisory Inc. now owns 543,763 shares of the biopharmaceutical company’s stock worth $5,721,000 after buying an additional 21,133 shares during the period. Finally, Nationwide Fund Advisors boosted its position in Omeros Corporation by 0.9% in the second quarter. Nationwide Fund Advisors now owns 67,255 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 631 shares during the period. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Omeros Corporation (NASDAQ:OMER) traded down 1.39% during trading on Monday, reaching $12.81. The company had a trading volume of 46,386 shares. Omeros Corporation has a one year low of $7.20 and a one year high of $16.80. The company has a 50-day moving average price of $9.87 and a 200 day moving average price of $10.86. The company’s market capitalization is $549.74 million.

Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $11.64 million. During the same quarter in the prior year, the company posted ($0.53) EPS. Omeros Corporation’s revenue for the quarter was up 253.1% on a year-over-year basis. Analysts expect that Omeros Corporation will post ($1.69) earnings per share for the current year.

A number of research firms have issued reports on OMER. Zacks Investment Research cut Omeros Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, November 16th. Wedbush decreased their price objective on Omeros Corporation from $56.00 to $47.00 and set an “outperform” rating for the company in a report on Wednesday, November 16th. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price objective on shares of Omeros Corporation in a report on Wednesday, August 10th. Maxim Group decreased their price objective on Omeros Corporation from $30.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Finally, WBB Securities restated a “buy” rating and issued a $75.00 price objective on shares of Omeros Corporation in a report on Thursday, November 17th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $33.23.

In other news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the transaction, the vice president now owns 179,597 shares in the company, valued at $1,959,403.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.60% of the company’s stock.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Related posts

Leave a Comment